Deka Biosciences (“Deka”), a clinical-stage biotechnology company headquartered at 20271 Goldenrod Lane in Germantown and focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced that the first subject has been dosed in a Phase 1 clinical trial of DK210 (EGFR) at NEXT Oncology in Fairfax, Virginia. The Phase 1, first-in-human, multicenter clinical study seeks to characterize the safety, potential efficacy and evaluate possible biomarkers of response to DK210 (EGFR) in patients with advanced solid cancer(s) who are expressing epidermal growth factor receptors (EGFR) (NCT05704985).
Per the press release: “We are beyond thrilled to begin the clinical trial of DK210 (EGFR), marking our first program to enter clinical development,” said John Mumm, Ph.D., President and CEO of Deka. “Importantly, we anticipate that the results of the study will confirm the clinical safety, pharmacokinetics, exploratory efficacy and correlative biomarker responses to our first DiakineTM, establishing a solid foundation for the expanded use of this treatment in cancer patients.”
Click here to read more via The MoCo Show.